

## Technology Guidance

# Nivolumab

## for treating resectable (tumours $\geq 4$ cm or node positive) non-small-cell lung cancer

Technology Guidance from the MOH Drug Advisory Committee

### Guidance Recommendations

The Ministry of Health's Drug Advisory Committee has recommended:

- ✓ Nivolumab 40 mg/4 mL, 100 mg/10 mL and 240 mg/24 mL concentrate for solution for infusion when used in combination with platinum-doublet chemotherapy for neoadjuvant treatment of resectable (tumours  $\geq 4$  cm or node positive) non-small-cell lung cancer. Maximum treatment duration: 3 cycles.

The decision was based on acceptable clinical effectiveness and pricing proposal by the company.

### Funding status

Nivolumab 40 mg/4 mL, 100 mg/10 mL and 240 mg/24 mL concentrate for solution for infusion are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 December 2026.

***Clinical indication, subsidy class and MediShield Life claims eligibility for nivolumab are provided in the Annex.***

## ANNEX

### Recommendations by the MOH Drug Advisory Committee

| Drug preparation                                                                          | Approved clinical indication                                                                                                                                                                       | Subsidy class (implementation date) | Eligible for MediShield Life claims (implementation date) |
|-------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|-----------------------------------------------------------|
| Nivolumab 40 mg/4 mL, 100 mg/10 mL and 240 mg/24 mL concentrate for solution for infusion | In combination with platinum-doublet chemotherapy for neoadjuvant treatment of resectable (tumours $\geq 4$ cm or node positive) non-small-cell lung cancer. Maximum treatment duration: 3 cycles. | MAF (1 Dec 2026)                    | Yes <sup>1</sup> (1 Apr 2023)                             |

Abbreviations: MAF, Medication Assistance Fund.

<sup>1</sup> Please refer to [MOH's website](#) for the MediShield Life claim limit starting from the implementation date.

 Agency for Care Effectiveness - ACE  Agency for Care Effectiveness (ACE)

#### About the Agency

The Agency for Care Effectiveness (ACE) was established by the Ministry of Health (Singapore) to drive better decision-making in healthcare through health technology assessment (HTA), clinical guidelines, and education.

As the national HTA agency, ACE conducts evaluations to inform government funding decisions for treatments, diagnostic tests and vaccines, and produces guidance for public hospitals and institutions in Singapore.

The guidance is not, and should not be regarded as, a substitute for professional or medical advice. Please seek the advice of a qualified healthcare professional about any medical condition. The responsibility for making decisions appropriate to the circumstances of the individual patient remains with the healthcare professional.

Find out more about ACE at <https://www.ace-hta.gov.sg/about-us/>

#### © Agency for Care Effectiveness, Ministry of Health, Republic of Singapore

All rights reserved. Reproduction of this publication in whole or in part in any material form is prohibited without the prior written permission of the copyright holder. Requests to reproduce any part of this publication should be addressed to:

Agency for Care Effectiveness, Ministry of Health, Singapore  
Email: [ACE@moh.gov.sg](mailto:ACE@moh.gov.sg)

In citation, please credit "Agency for Care Effectiveness, Ministry of Health, Singapore" when you extract and use the information or data from the publication.